<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>M. genavense on ntmscope</title>
    <link>http://ntmscope.org/tags/m.-genavense/</link>
    <description>Recent content in M. genavense on ntmscope</description>
    <generator>Source Themes academia (https://sourcethemes.com/academic/)</generator>
    <language>en-us</language>
    <copyright>Copyright &amp;copy; {year}</copyright>
    <lastBuildDate>Mon, 04 Jul 2022 00:00:00 +0000</lastBuildDate>
    
	    <atom:link href="http://ntmscope.org/tags/m.-genavense/index.xml" rel="self" type="application/rss+xml" />
    
    
    <item>
      <title>ESM Paper of the Quarter award</title>
      <link>http://ntmscope.org/news/post4/</link>
      <pubDate>Mon, 04 Jul 2022 00:00:00 +0000</pubDate>
      
      <guid>http://ntmscope.org/news/post4/</guid>
      <description>&lt;img src=&#34;featured.png&#34;&gt;
&lt;br&gt;
The ntmscope-publication &#34;High overall mortality of &lt;i&gt;Mycobacterium genavense&lt;/i&gt; infections and impact of antimycobacterial therapy: Systematic review and individual patient data meta-analysis&#34; has been awarded ESM&#39;s &#34;Paper of the Qarter Award&#34; for Q4 2021.
&lt;br&gt;
&lt;br&gt;
We are very thankful for the positive feedback. The prize money will be invested in future and ongoing ntmscope-projects.
&lt;br&gt;
&lt;br&gt;
See the news at the European Society of Mycobacteriology&#39;s &lt;a href=&#34;https://www.esmycobacteriology.eu/paper-of-the-quarter&#34;&gt;homepage&lt;/a&gt;
&lt;br&gt;
&lt;br&gt;
See the publication at &lt;a href=&#34;http://ntmscope.org/publication/yjinf_2021&#34;&gt;ntmcope.org&lt;/a&gt;</description>
    </item>
    
    <item>
      <title>ntmscope_meta</title>
      <link>http://ntmscope.org/project/meta/</link>
      <pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate>
      
      <guid>http://ntmscope.org/project/meta/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Introduction&lt;/strong&gt;: Treatment and management of rare NTM remains a considerable challenge as randomized controlled trials or systematic studies are scarce. Most therapeutic recommendations are based on &lt;em&gt;in vitro&lt;/em&gt; data or clinical experience with more frequent NTM. The optimal therapy for most infections remains unclear.
&lt;br&gt;
&lt;br&gt;
&lt;strong&gt;Objectives&lt;/strong&gt;: Investigation of clinical data regarding the clinical manifestations and therapeutic outcomes of rare NTM.
&lt;br&gt;
&lt;br&gt;
&lt;strong&gt;Methods&lt;/strong&gt;: Literature review, (individual patient data) meta analysis.
&lt;br&gt;
&lt;br&gt;
&lt;strong&gt;Status&lt;/strong&gt;: &lt;em&gt;Ongoing&lt;/em&gt;&lt;/p&gt;
&lt;p&gt;&lt;br&gt;
&lt;a href=&#34;http://ntmscope.org/#contact&#34;&gt;Contribute&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
  </channel>
</rss>
